Endocardial to expand with $12.7 million finance:
This article was originally published in Clinica
Executive Summary
Endocardial Solutions has closed a $12.7 million private placement to institutional investors. The St Paul, Minnesota-based company, which develops and manufactures technology for mapping complex arrhythmias, will use the funds to "move full speed on several fronts". These include US market expansion, clinical trials for atrial fibrillation, and software and hardware product development to further enhance the Ensite 3000 system's mapping and navigational technology.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.